The discovery of biomarkers such as phospho-tau217 marked an important advancement in Alzheimer’s diagnosis. This particular ...

The possibility of early screening for Alzheimer's disease with a simple blood test is increasingly approaching. Dementia is a serious health problem around the world, and Korea is also interested in ...

Encouraging interim results have supported Roche’s decision to move trontinemab into a pivotal Phase III programme.

In this video Thomas Wisniewski, MD, director of NYU Langone’s Alzheimer’s Disease Research Center, discusses recent advancements in Alzheimer's disease care.

Levels of tau in the brain - measured either post-mortem or using PET imaging techniques - have ... Pharmacology "The long debate about tau vs beta-amyloid... will ultimately be resolved where ...

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced the launch of a new laboratory blood test designed to help ...

Biomarker and cognitive data supported treatment with the anti-amyloid agent lecanemab (Leqembi) for up to 36 months in early Alzheimer's disease, initial findings from the CLARITY AD open-label ...

A study in Alzheimer’s & Dementia, a leading journal in dementia research, has demonstrated the high accuracy of plasma ...